Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells

He, Chang-xi; Ai, Jing; Xing, Wei-qiang; Chen, Yi; Zhang, Hao-tian; Huang, Min; Hu, You-hong; Ding, Jian; Geng, Mei-yu
January 2014
Acta Pharmacologica Sinica;Jan2014, Vol. 35 Issue 1, p89
Academic Journal
Aim:c-Met kinase deregulation is strongly associated with the formation, progression and dissemination of human cancers. In this study we identified Yhhu3813 as a small-molecule inhibitor of c-Met kinase and characterized its antitumor properties both in vitro and in vivo.Methods:The activities of different kinases were measured using ELISA assays and signaling proteins in the cells were detected with Western blotting. Cell proliferation was assessed using SRB or MTT assay in twenty human cell lines and cell cycle distribution was determined with flow cytometry. Transwell-based assay was used to evaluate cell migration and invasion. Cell invasive growth was detected by a morphogenesis assay. c-Met overactivated human NSCLC cell line EBC-1 xenografts were used to evaluate the in vivo anti-tumor efficacy.Results:Yhhu3813 potently inhibited c-Met kinase activity in vitro with an IC50 value of 2.4±0.3 nmol/L, >400-fold higher than that for a panel of 15 different tyrosine kinases, suggesting a high selectivity of Yhhu3813. The compound (20, 100 and 500 nmol/L) dose-dependently inhibited the phosphorylation of c-Met and its key downstream Akt and Erk signal cascades in multiple c-Met aberrant human cancer cell lines, regardless of the mechanistic complexity in c-Met activation across different cellular contexts. In 20 human cancer cell lines harboring different backgrounds of c-Met expression/activation, Yhhu3813 potently inhibited c-Met-driven cell proliferation via arresting cells at G1/S phase. Furthermore, Yhhu3813 substantially impaired c-Met-mediated cell migration, invasion, scattering, and invasive growth. Oral administration of EBC-1 xenograft mice with Yhhu3813 (50 or 100 mg·kg−1·d−1, qd, for 2 weeks) dose-dependently suppressed the tumor growth, which was correlated with a reduction in the intratumoral proliferation index and c-Met signaling.Conclusion:Yhhu3813 is a potent selective inhibitor of c-Met that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells in vitro and in vivo.


Related Articles

  • The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer. Allen, Joshua E.; Gallant, Jean-Nicolas; Dicker, David T.; Amin, Shantu; Irby, Rosalyn B.; Sharma, Arun K.; El-Deiry, Wafik S. // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Phenylbutyl isoselenocyanate (ISC-4) is an Akt inhibitor with demonstrated preclinical efficacy against melanoma and colon cancer. In this study, we sought to improve the clinical utility of ISC-4 by identifying a synergistic combination with FDA-approved anti-cancer therapies, a relevant and...

  • Precision cancer medicine: where to target? Yu, Qiang; Ding, Jian // Acta Pharmacologica Sinica;Oct2015, Vol. 36 Issue 10, p1161 

    No abstract available.

  • Signal Transduction Pathways of Taxanes-Induced Apoptosis. V. Ganansia-Leymarie; P. Bischoff; J-P. Bergerat; V. Holl // Current Medicinal Chemistry - Anti-Cancer Agents;Jul2003, Vol. 3 Issue 4, p291 

    Docetaxel (Taxotere) is a member of the taxane class of anticancer agents to reach clinical use. This semisynthetic analog of paclitaxel (Taxol) is one of the newer potent anti-neoplastic agents now undergoing extensive laboratory and clinical investigations. Several studies indicate that...

  • The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Luo, B; Lee, A S // Oncogene;2/14/2013, Vol. 32 Issue 7, p805 

    Cancer progression is characterized by rapidly proliferating cancer cells that are in need of increased protein synthesis. Therefore, enhanced endoplasmic reticulum (ER) activity is required to facilitate the folding, assembly and transportation of membrane and secretory proteins. These...

  • Smad phosphoisoform signaling specificity: the right place at the right time. Matsuzaki, Koichi // Carcinogenesis;Nov2011, Vol. 32 Issue 11, p1578 

    Transforming growth factor (TGF)-β antagonizes mitogenic Ras signaling during epithelial regeneration, but TGF-β and Ras act synergistically in driving tumor progression. Insights into these apparently contradictory effects have come from recent detailed analyses of the TGF-β signaling...

  • STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia. MUNOZ, JAVIER; DHILLON, NAVJOT; JANKU, FILIP; WATOWICH, STEPHANIE S.; HONG, DAVID S. // Oncologist;2014, Vol. 19 Issue 5, p536 

    The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is an active mediator of cytokine signaling in the pathogenesis of solid and hematologic malignancies. The seven-member STAT family is composed of latent cytoplasmic transcription factors that are...

  • Correction: Podocalyxin Promotes Glioblastoma Multiforme Cell Invasion and Proliferation via β-Catenin Signaling. null, null // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    No abstract available.

  • High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma. Zhang, Shi-Hong; Wang, Chan-Juan; Shi, Ling; Li, Xing-Hua; Zhou, Jing; Song, Li-Bing; Liao, Wen-Ting // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: The flotillin family member flotillin-1 (FLOT1) encodes a caveolae-associated, integral membrane protein that belongs to lipid raft family and involves in vesicular trafficking and signal transduction. However, the role of FLOT1 in development and progression of cancer remains...

  • Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Lattanzio, Laura; Tonissi, Federica; Monteverde, Martino; Vivenza, Daniela; Russi, Elvio; Milano, Gérard; Merlano, Marco; Lo Nigro, Cristiana // Investigational New Drugs;Apr2015, Vol. 33 Issue 2, p310 

    Introduction In complement to anti-EGFR therapy, the targeting of PI3K/AKT/mTOR signaling pathway is of particular interest in the management of Head and Neck Squamous Cell Carcinoma (HNSCC). Here, we assess the effects of PI3K inhibition combined with anti-EGFR monoclonal antibody cetuximab...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics